Roth Capital Resumes Neogenomics (NEO) at Buy
Tweet
Share
E-mailGet Alerts NEO Hot Sheet
Price: $11.43 +2.05%
Rating Summary:
14 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Rating Summary:
14 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Join SI Premium – FREE
Roth Capital resumed coverage on Neogenomics (NASDAQ: NEO) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on Neogenomics click here. For more ratings news on Neogenomics click here.
Shares of Neogenomics closed at $8.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lake Street Starts Vivani Medical, Inc. (VANI) at Buy
- Deutsche Bank Starts Insulet Corporation (PODD) at Buy
- Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
